<DOC>
	<DOCNO>NCT00308282</DOCNO>
	<brief_summary>This study multicenter , double-blind , study evaluate safety effectiveness treatment LY2127399 ( addition standard care treatment , methotrexate ) patient Rheumatoid Arthritis . Patients receive three intravenous dos LY2127399 placebo . Patients participate 10 visit study site , 6 month . Evaluation safety efficacy conduct throughout study .</brief_summary>
	<brief_title>A Multi-Site Study Evaluate Safety Effect Study Drug Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Male female age 18 75 year Have give write informed consent approval Women must risk become pregnant study participation Diagnosis Rheumatoid Arthritis Current , regular use Methotrexate , stable dose Use exclude medication ( review study doctor ) Surgical treatment joint assess study Are unable ambulate ; , confine bed wheelchair bound Have medical finding , opinion study doctor , put patient unacceptable risk participation study Have recent ongoing infection , opinion study doctor put patient unacceptable risk participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2008</verification_date>
</DOC>